A Step Inside: Wearable Tech Validates Gait as a Digital Biomarker for Parkinson’s
A new study in the Annals of Clinical and Translational Neurology validates the use of wearable digital insoles for assessing gait in Parkinson’s disease. Researchers compared the Moticon ReGo Insole against the gold-standard GAITRite system in 21 patients, both in medication “OFF” and “ON” states. The insoles demonstrated excellent agreement for measuring gait cadence, speed, and stride length, with these parameters also showing significant correlations with clinical rating scale scores. The technology successfully detected significant differences in gait metrics between medication states, and patients reported the insoles were comfortable and user-friendly.
Why it might matter to you: This research highlights the growing role of objective, continuous digital biomarkers in neuropsychiatry, moving beyond subjective clinical scales. For professionals managing complex neurocognitive and movement disorders, such tools could refine treatment monitoring, especially for medication response. It points toward a future where remote patient monitoring and precise, data-driven assessments become integral to managing chronic neurological conditions.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
